MEA Autoinjectors Market

MEA Autoinjectors Market Size (2023 to 2028)

The size of the Autoinjectors Market in the Middle East & Africa was worth USD 0.24 billion in 2023 and estimated to be growing at a CAGR of 15.182%, to reach USD 0.56 billion by 2028.

The market for autoinjectors in the MEA region is expected to be driven by the proliferation of various chronic diseases, increasing preference for self-administration of drugs, and the availability of generic versions of autoinjectors across the region. Also, favorable reimbursement policies and technological advancements in the healthcare sector are expected to boost market growth. In addition, the autoinjectors market is further accelerating due to the increased prevalence of anaphylaxis in MEA.

Furthermore, the major companies in the region are focussing on conducting research and development activities that are expected to impact the market growth positively. These efforts aim to develop simple, cost-effective, and cutting-edge technology-based autoinjectors to treat chronic diseases, including rheumatoid arthritis and multiple sclerosis. During the forecast period, such advancements are expected to fuel market growth. Moreover, the rising number of approvals and the supportive government initiatives and investments are expected to provide lucrative growth opportunities for the market players. 

The World Health Organization (WHO), the Food and Drug Administration (FDA), and different country-based medical regulatory organizations have approved regulatory approvals for the various pharmaceutical or biotechnology companies in the region, expected to expand the MEA regional market growth. Over the projection period, the home care settings category is predicted to be the fastest-growing. The quickest growth of this sector can be attributed to the increasing usage of home healthcare devices, which is due to the growing geriatric population and the rising prevalence of diabetes.

The preference for alternate medication delivery channels such as oral diabetic treatments and nasal epinephrine sprays, on the other hand, is likely to restrict autoinjector device adoption in this region.

This research report on the MEA Autoinjectors market has been segmented & sub-segmented the market into the following categories:

By Product:  

• Fillable Autoinjectors
• Prefilled Autoinjectors

By Usability: 

• Disposable Autoinjectors
• Reusable Autoinjectors

By Manufacturing Design: 

• Standardized Autoinjectors
• Customized Autoinjectors

By Technology: 

• Automated Autoinjectors
• Manual Autoinjectors

By Application: 

• Anaphylaxis
• Multiple Sclerosis
• Rheumatoid Arthritis

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Regionally, the market is growing slowly because of the region's many problems in battles and the unstable economy. However, countries like the USA, China, and the UK are investing in the region, and this increased financial revenue aids the healthcare sectors in this region. As a result, the MEA Autoinjectors Market is estimated to account for a moderate share in the global market during the forecast period. The region's market growth is attributed to the increasing prevalence of chronic and lifestyle diseases, improving healthcare infrastructure, and advancements in medical device technologies. On the other hand, the novel drug formulations, improvements in drug delivery methods, and favorable regulatory laws allow the market to grow. As a result, the major countries in the region, such as South Africa, Saudi Arabia, and UAE, are expanding the MEA regional market growth.

South Africa accounted for the largest share of the MEA Autoinjectors market in 2020, and it is likely to continue its growth during the forecast period. The major companies in the autoinjectors market are concentrating their efforts on creating technical solutions for autoinjectors to fulfill the need for a viscous biologics delivery mechanism.

Saudi Arabia and UAE are projected to witness a considerable share in the MEA Autoinjectors Market during the forecast period. The Growing incidence of diabetes and anaphylaxis due to food allergies in the countries such as the United Arab Emirates and Saudi Arabia are expected to augment the market growth. Moreover, the prevalence of diabetes 1 is projected to propel market growth.

KEY MARKET PLAYERS:

A few of the MEA Autoinjectors market players covered in this report are Mylan N.V., Pfizer, Inc., Bayer AG, Becton, Dickinson and Company, Novartis AG, Biogen Idec, Inc., Janssen North America Services, LLC, Sanofi, Unilife Corporation, and Eli Lilly.